Merck Singulair Is Top Asthma Controller In U.S., Headed For $1.2 Bil. Sales
Merck's asthma drug Singulair (montelukast sodium) appears headed for close to $1.2 bil. in sales for the full year after reaching $675 mil. through the first six months.
You may also be interested in...
Merck's Vioxx sales are showing the impact of a slower penetration rate of COX-2 inhibitors into the analgesic market, the company said June 22.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials